APTEEA Therapeutics

Apteea Therapeutics is a French biotechnology company dedicated to the discovery and development of aptamer-based drugs, often referred to as "chemical antibodies." Spun out from the University of Bordeaux and the ARNA Laboratory, the company leverages decades of expertise in oligonucleotide selection to target high-unmet-need conditions, with a primary focus on glioblastoma. Their platform enables the creation of synthetic ligands that can cross the blood-brain barrier and deliver therapeutic agents with high precision. By utilizing aptamers, Apteea aims to offer advantages over traditional biologics, including lower immunogenicity, enhanced stability, and more efficient tissue penetration. The company is currently advancing its lead programs through the pre-clinical stage while seeking strategic partnerships for its discovery platform.